Prolytix, a U.S.-based provider of bioanalytical and protein characterization services, has acquired 60 validated assays previously owned by Hemostasis Reference Laboratory, a global reference lab focused on thrombosis and hemostasis testing. Financial terms were not disclosed.
The acquisition is intended to create an end-to-end thrombosis and hemostasis analytical services offering by combining Prolytix’s protein science capabilities with HRL’s clinical and specialty coagulation testing expertise. Prolytix said the expanded portfolio will support work spanning sample collection, research reagents, release and stability testing of protein therapeutics, and advanced bioanalytical testing services.
Prolytix also said it is expanding its ability to support GLP-, GCP-, and CLIA-compliant work within dedicated laboratory space. The company noted it recently received a CLIA Certificate of Compliance and said the accompanying inspection report cited no deficiencies.
Prolytix, formerly Haematologic Technologies, Inc., said it has more than 35 years of experience supporting the research, development, and commercialization of large-molecule biotherapeutics and producing reagents for coagulation research.
KEY QUOTES:
“This marks an exciting step forward as we continue expanding our capabilities to support GLP, GCP, and CLIA-compliant work within a dedicated laboratory space. The recent award of our CLIA Certificate of Compliance—accompanied by an inspection report citing no deficiencies—underscores the quality and rigor of our operations. With the addition of these assays, we significantly enhance our clinical and translational testing capacity, further strengthening Prolytix as a leader in hemostasis.”
Ryan Dorfman, COO, Prolytix
“This is a natural and exciting fit. Our teams share a deep commitment to scientific integrity and advancing the field, and will now be able to provide a more comprehensive solution that supports biopharmaceutical companies developing novel therapies in thrombosis, coagulation disorders, and hematologic disease.”
Joanne McGrath, Manager, Laboratory Services, Hemostasis Reference Laboratory
